Difference between revisions of "Template:Antiarrhythmic agents"
Jump to navigation
Jump to search
m (67 revisions imported) |
|||
| (62 intermediate revisions by 30 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | {{Navbox | |
| − | + | | name = Antiarrhythmic agents | |
| − | | | + | | title = [[Antiarrhythmic agent]]s ([[ATC code C01#C01B|C01B]]) |
| − | + | | state = {{{state|autocollapse}}} | |
| − | | | + | |listclass = hlist |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |}< | + | |group1 = [[Channel blocker]]s |
| − | [[ | + | |list1 = {{Navbox|subgroup |
| + | |||
| + | | group1 = [[Antiarrhythmic agent#Class I agents|class I]]<BR>([[sodium channel blocker|Na<sup>+</sup> channel blockers]]) | ||
| + | | list1 = {{Navbox|subgroup | ||
| + | |||
| + | | group1 = class Ia ([[Cardiac action potential#Phase 0|Phase 0]]→ and [[Cardiac action potential#Phase 3|Phase 3]]→) | ||
| + | | list1 = | ||
| + | * [[Ajmaline]] | ||
| + | * [[Disopyramide]] | ||
| + | * [[Dihydroquinidine|Hydroquinidine]] | ||
| + | * [[Lorajmine]] | ||
| + | * [[Prajmaline]] | ||
| + | * [[Procainamide]]<sup>#</sup> | ||
| + | * [[Quinidine]]<sup>#</sup> | ||
| + | * [[Sparteine]] | ||
| + | |||
| + | | group2 = class Ib ([[Cardiac action potential#Phase 3|Phase 3]]←) | ||
| + | | list2 = | ||
| + | * ''[[Intravenous therapy|IV]]'' | ||
| + | ** [[Lidocaine]]<sup>#</sup> | ||
| + | * ''[[enteral]]'' | ||
| + | ** [[Aprindine]] | ||
| + | ** [[Mexiletine]] | ||
| + | ** [[Tocainide]] | ||
| + | |||
| + | | group3 = class Ic ([[Cardiac action potential#Phase 0|Phase 0]]→) | ||
| + | | list3 = | ||
| + | * [[Encainide]]<sup>‡</sup> | ||
| + | * [[Ethacizine]] | ||
| + | * [[Flecainide]] | ||
| + | * [[Indecainide]]<sup>‡</sup> | ||
| + | * [[Lorcainide]] | ||
| + | * [[Moracizine]]<sup>‡</sup> | ||
| + | * [[Propafenone]] | ||
| + | |||
| + | }} | ||
| + | |||
| + | | group3 = [[Antiarrhythmic agent#Class III agents|class III]]<BR>([[Cardiac action potential#Phase 3|Phase 3]]→, [[potassium channel blocker|K<sup>+</sup> channel blockers]]) | ||
| + | | list3 = | ||
| + | * [[Amiodarone]] | ||
| + | * [[Bretylium]] | ||
| + | * [[Bunaftine]] | ||
| + | * [[Celivarone]]<sup>†</sup> | ||
| + | * [[Dofetilide]] | ||
| + | * [[Dronedarone]] | ||
| + | * [[E-4031]]<sup>†</sup> | ||
| + | * [[Ibutilide]] | ||
| + | * [[Nifekalant]] | ||
| + | * [[Sotalol]] | ||
| + | * [[Tedisamil]] | ||
| + | * [[Vernakalant]] | ||
| + | |||
| + | | group4 = [[Antiarrhythmic agent#Class IV agents|class IV]]<br/>([[Cardiac action potential#Phase 4|Phase 4]]→, [[calcium channel blocker|Ca<sup>2+</sup> channel blockers]]) | ||
| + | | list4 = | ||
| + | * [[Diltiazem]] | ||
| + | * [[Verapamil]]<sup>#</sup> | ||
| + | |||
| + | }} | ||
| + | |||
| + | |group2 = [[Receptor (biochemistry)|Receptor]] [[agonist]]s<BR>and [[Receptor antagonist|antagonist]]s | ||
| + | |list2 = {{Navbox|subgroup | ||
| + | |||
| + | | group2 = [[Antiarrhythmic agent#Class II agents|class II]]<br/>([[Cardiac action potential#Phase 4|Phase 4]]→, [[beta blocker|β blocker]]s) | ||
| + | | list2 = | ||
| + | * [[Nadolol]] | ||
| + | * [[Pindolol]] | ||
| + | * [[Propranolol]] | ||
| + | * ''cardioselective'' | ||
| + | ** [[Acebutolol]] | ||
| + | ** [[Atenolol]] | ||
| + | ** [[Esmolol]] | ||
| + | ** [[Metoprolol]] | ||
| + | |||
| + | | group5 = [[adenosine A1 receptor|A<sub>1</sub> agonist]] | ||
| + | | list5 = | ||
| + | * [[Adenosine]] | ||
| + | * [[Benzodiazepine]]s | ||
| + | * [[Barbiturate]]s | ||
| + | |||
| + | | group6 = [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]] | ||
| + | | list6 = | ||
| + | * [[muscarinic antagonist]]: [[Atropine]] | ||
| + | * [[Disopyramide]] | ||
| + | * [[Quinidine]]<BR>[[muscarinic agonist]]: [[Digoxin]] | ||
| + | |||
| + | | group7 = [[Adrenergic receptor#.CE.B1 receptors|α receptors]] | ||
| + | | list7 = | ||
| + | * [[Amiodarone]] | ||
| + | * [[Bretylium]] | ||
| + | * [[Quinidine]] | ||
| + | * [[Verapamil]] | ||
| + | |||
| + | }} | ||
| + | |||
| + | | group8 = [[Ion transporter]]s | ||
| + | | list8 = {{Navbox|subgroup | ||
| + | |||
| + | | group1 = [[Na+/K+-ATPase|Na<sup>+</sup>/ K<sup>+</sup>-ATPase]] | ||
| + | | list1 = | ||
| + | * [[Digitoxin]] | ||
| + | * [[Digoxin]] | ||
| + | * [[Ouabain]] | ||
| + | |||
| + | }} | ||
| + | |||
| + | | group9 = | ||
| + | | list9 = {{PharmNavFootnote}} | ||
| + | |||
| + | }}<noinclude> | ||
| + | {{collapsible option}} | ||
| + | [[Category:Antiarrhythmic agents]] | ||
| + | [[Category:Drug templates by ATC]] | ||
</noinclude> | </noinclude> | ||
Latest revision as of 14:15, 22 October 2020
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Antiarrhythmic agents|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Antiarrhythmic agents|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Antiarrhythmic agents|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.